FFUND is proud to have assisted ExoVectory, UMC Utrecht, and EVerZom in getting awarded the Eurostars grant (total value project €1,5Mio) for their innovative approach to developing an ex vivo engineered T-cell therapy against cancer.
Eurostars
Eurostars, a program initiated by Eureka, is a funding platform aimed at supporting innovative small and medium-sized enterprises in collaborative research and development projects across Europe.
About the consortium
ExoVectory is pioneering an advanced technology facilitating the efficient loading of DNA and ribonucleoprotein particles into extracellular vesicles (EVs) for CRISPR/Cas9-based genome editing, particularly for the ex vivo engineering of therapeutic T-cells. With University Medical Center Utrecht (UMCU) specialized in EV isolation and characterization, and French SME EVerZom excelling in scalable and clinically compatible EV manufacturing technology, the EVECTOR consortium is joining forces to develop an unparalleled delivery system for therapeutic gene editing.
What is the project about?
While viral vectors are the gold standard for gene therapies, they come with significant safety and implementation constraints. EVs present a promising alternative but are currently hindered by challenges in accommodating nucleic acids or proteins within them, as well as cost-effective production. The EVECTOR project aims to overcome these obstacles. Through the consortium’s innovative approach, we are getting one step closer towards personalized healthcare with more effective treatments and fewer side effects.
How did FFUND help?
Founder and CSO, Jeroen de Vrij: “FFUND’s guidance and strategic insights were pivotal in crafting a winning proposal, aligning with funding priorities. Their expertise ensured our application stood out, leading to successful approval.”
